Cognition Therapeutics Aligns with FDA on Pivotal DLB Psychosis Trial for Zervimesine
Event summary
- Cognition Therapeutics received FDA alignment on key aspects of a pivotal trial for zervimesine in DLB psychosis, with the registrational program expected to begin mid-2027.
- The Phase 3 study will enroll DLB patients experiencing hallucinations and delusions, randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine months.
- Zervimesine demonstrated an 89% slowdown in progression of hallucinations and delusions in a recent Phase 2 analysis.
- The company will work with the FDA on using the neuropsychiatric inventory (NPI) as a novel primary endpoint.
The big picture
Cognition Therapeutics is advancing its lead candidate, zervimesine, into a pivotal trial for DLB psychosis, an area with no approved treatments. The FDA's alignment on the trial design marks a significant step forward in addressing this debilitating condition, which affects up to 80% of DLB patients. The company's focus on durable treatment options that slow disease progression aligns with broader industry trends toward targeted therapies for neurodegenerative diseases.
What we're watching
- Regulatory Pathway
- Whether the FDA's acceptance of NPI as a primary endpoint will streamline the approval process for zervimesine.
- Clinical Execution
- The pace at which Cognition can initiate and complete the Phase 3 trial, given the mid-2027 start date.
- Market Opportunity
- How zervimesine's potential approval could address the critical unmet need in DLB psychosis, currently reliant on off-label antipsychotics.